Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Targeting the Vital Non-Structural Proteins (Nsp12, Nsp7, Nsp8 and Nsp3) From Sars-Cov-2 and Inhibition of Rna Polymerase by Natural Bioactive Compound Naringenin As a Promising Drug Candidate Against Covid-19 Publisher



Aleebrahimdehkordi E1, 2, 3 ; Ghoshouni H4 ; Koochaki P5 ; Esmailidehkordi M6 ; Aleebrahim E7 ; Chichagi F8 ; Jafari A2, 9, 10 ; Hanaei S11, 12 ; Heidarisoureshjani E13, 14 ; Rezaei N11, 12, 15
Authors
Show Affiliations
Authors Affiliations
  1. 1. Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. Nutritional Health Team (NHT), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
  4. 4. Medical student, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  5. 5. Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States
  6. 6. Pharmacologist, Shahrekord, Iran
  7. 7. PhD Student in Food Sciences and Engineering, Islamic Azad University, Tehran North Branch, Tehran, Iran
  8. 8. Research Development Center, Sina Hospital, Tehran University of Medical Science, Tehran, Iran
  9. 9. Student Research Committee, Department of Nutrition, School of Health, Golestan University of Medical Sciences, Gorgan, Iran
  10. 10. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
  11. 11. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  12. 12. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  13. 13. Department of Biology, Faculty of Science, Shahrekord University, P. O. Box. 115, Shahrekord, Iran
  14. 14. Central Laboratory, Shahrekord University, Shahrekord, Iran
  15. 15. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Molecular Structure Published:2023


Abstract

The prevalence of SARS-CoV-2-induced respiratory infections is now a major challenge worldwide. There is currently no specific antiviral drug to prevent or treat this disease. Infection with COVID-19 seriously needs to find effective therapeutic agents. In the present study, naringenin, as a potential inhibitor candidate for RNA Polymerase SARS-CoV-2 was compared with remdesivir (FDA-approved drug) and GS-441,524 (Derivative of the drug remdesivir) by screening with wild-type and mutant SARS-CoV-2 NSP12 (NSP7-NSP8) and NSP3 interfaces, then complexes were simulated by molecular dynamics (MD) simulations to gain their stabilities. The docking results displayed ​scores of -3.45 kcal/mol and -4.32 kcal/mol against NSP12 and NSP3, respectively. Our results showed that naringenin had ΔG values more negative than the ΔG values of Remdesivir (RDV) and GS-441,524. Hence, naringenin was considered to be a potential inhibitor. Also, the number of hydrogen bonds of naringenin with NSP3 and later NSP12 are more than Remdesivir and its derivative. In this research, Mean root mean square deviation (RMSD) values of NSP3 and NSP12with naringenin ligand (5.55±1.58 nm to 3.45±0.56 nm and 0.238±0.01 to 0.242±0.021 nm, respectively showed stability in the presence of ligand. The root mean square fluctuations (RMSF) values of NSP3 and NSP12 amino acid units in the presence of naringenin in were 1.5 ± 0.31 nm and 0.118±0.058, respectively. Pharmacokinetic properties and prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of naringenin and RDV showed that ​these two compounds had no potential cytotoxicity. © 2023
Other Related Docs
9. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
20. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
21. Structure-Based Virtual Screening for Defeating Drug Resistant Form of Egfr Protein, Combinatorial Chemistry and High Throughput Screening (2016)
33. Crispr/Cas13: A Potential Therapeutic Option of Covid-19, Biomedicine and Pharmacotherapy (2020)
35. Precision Medicine in Infectious Disease, Precision Medicine in Clinical Practice (2022)